TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12953141

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 0
Study: 10348390

Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Day centre rehabilitation
Number of subjects: 105
Study: 7724182

Group type: EXPERIMENTAL
Intervention: Intensive therapy (three or more daily insulin injections or continuous subcutaneous insulin infusion, guided by four or more glucose tests daily)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study: 1994639

Group type: EXPERIMENTAL
Intervention: Cytobrush plus Ayre spatula
Number of subjects: 802

Group type: COMPARATOR
Intervention: Cervex brush
Number of subjects: 802
Study: 6116608

Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Syrosingopine
Number of subjects: 20
Study: 31553890

Group type: EXPERIMENTAL
Intervention: Rest-redistribution (RR; 20 sets of 2 with 15 s inter-set rest)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional sets (TS; 4 sets of 10 with 95 s inter-set rest)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rest-redistribution (RR)
Number of subjects: 0
Study: 28122642

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Presence of interstitial pneumonia
Number of subjects: 900
Study: 27207886

Group type: EXPERIMENTAL
Intervention: 4-week oral administration of S-1 (80-120 mg/body/day) followed by a 2-week rest (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2-week oral administration of S-1 (80-120 mg/body/day) followed by a 1-week rest (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 80
Study: 23963633

Group type: EXPERIMENTAL
Intervention: 28.2 μg teriparatide
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo (1.4 μg teriparatide)
Number of subjects: 316
Study: 23358401

Group type: EXPERIMENTAL
Intervention: 131I‐iodide activity calculated based on desired 'optimal' final thyroid mass (Group D)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 400 Gy absorbed thyroid dose (Group C)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 200 Gy absorbed thyroid dose (Group B)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 100 Gy absorbed thyroid dose (Group A)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 131I‐iodide activity for Group C
Number of subjects: 147

Group type: COMPARATOR
Intervention: 131I‐iodide activity for Group D
Number of subjects: 147
Study: 20395842

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1194

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1194
Study: 18234321

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg twice daily
Number of subjects: 447
Study: 16008596

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (TG) induction therapy (1.5 mg/kg/dose during the anhepatic period and QOD x2 doses)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (TG) induction therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: No Thymoglobulin (control group)
Number of subjects: 22
Study: 12974921

Group type: EXPERIMENTAL
Intervention: On-pump/beating heart surgery (Group II)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional surgery (Group I)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 10392509

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 78
Study: 8681616

Group type: EXPERIMENTAL
Intervention: External chest wall oscillation (ECWO) at 1 Hz
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cuirass without ECWO (Control)
Number of subjects: 7
Study: 8375238

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 38
Study: 3079781

Group type: EXPERIMENTAL
Intervention: Encainide 25 mg four times/day
Number of subjects: 187

Group type: COMPARATOR
Intervention: Quinidine 200 mg four times/day
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Encainide 50 mg four times/day (after dose adjustment)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Quinidine 400 mg four times/day (after dose adjustment)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 187

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 187
Study: 29806666

Group type: EXPERIMENTAL
Intervention: Central group (natural position)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Palatal group (3 mm more palatally)
Number of subjects: 30
Study: 26304041

Group type: EXPERIMENTAL
Intervention: rLH 150 IU/day added to rFSH 300 IU/day and GnRH antagonist 0.25 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: rFSH 300 IU/day and GnRH antagonist 0.25 mg/day (Control)
Number of subjects: 63
Study: 23788002

Group type: EXPERIMENTAL
Intervention: ω-3 FA-enriched oral nutrition supplement (200 mL twice daily providing 2.0 g EPA and 1.0 g DHA per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oral nutrition supplement (ONS)
Number of subjects: 0
Study: 24531662

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care 3 times weekly in addition to usual medical care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 50
Study: 21767441

Group type: EXPERIMENTAL
Intervention: 5 mg Lu AA21004
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: 10 mg Lu AA21004
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: 225 mg venlafaxine XR
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 19561345

Group type: EXPERIMENTAL
Intervention: Flexible three‐holed epidural catheter
Number of subjects: 500

Group type: COMPARATOR
Intervention: Flexible end‐holed epidural catheter
Number of subjects: 500
Study: 17467923

Group type: EXPERIMENTAL
Intervention: Interstitial Brachytherapy (IB)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prone Helical Tomotherapy (PT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiotherapy (3D-CRT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Supine Helical Tomotherapy (ST)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 13
Study: 12478879

Group type: EXPERIMENTAL
Intervention: Myo-inositol, 12 g daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (d‐glucose, 12 g daily)
Number of subjects: 11
Study: 10531773

Group type: EXPERIMENTAL
Intervention: 20 micrograms of purified Hepatitis B Surface Antigen (Euvax B, LG Chemicals) by i.m. injection in the deltoid (Group A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 5 micrograms intra-dermally (Group B)
Number of subjects: 61
Study: 8915800

Group type: EXPERIMENTAL
Intervention: Topical steroids
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) and a soft contact lens
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Long-term NSAID administration
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Management suggestions for severe haze and regression and steroid-induced elevated intraocular pressure
Number of subjects: 75
Study: 1810619

Group type: EXPERIMENTAL
Intervention: Mouthguard 1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mouthguard 2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mouthguard 3
Number of subjects: 17

Group type: COMPARATOR
Intervention: No mouthguard
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mouthguards (1, 2, 3) during heavy workload
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mouthguards (1, 2, 3) during light workload
Number of subjects: 17
Study: 6136289

Group type: EXPERIMENTAL
Intervention: Lorazepam premedication
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31879855

Group type: EXPERIMENTAL
Intervention: Bilateral scalp block with 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 30476030

Group type: EXPERIMENTAL
Intervention: Articles co-authored by statisticians
Number of subjects: 136

Group type: COMPARATOR
Intervention: Articles not co-authored by statisticians
Number of subjects: 136
Study: 29972002

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (acupuncture, acupoint injection, auricular point pressing)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 126

Group type: COMPARATOR
Intervention: Western medication (oral mecobalamin, 0.5 mg, 3 times a day for 3 weeks)
Number of subjects: 126
Study: 26518201

Group type: EXPERIMENTAL
Intervention: QoR‐15C
Number of subjects: 470

Group type: COMPARATOR
Intervention: PQRS
Number of subjects: 470
Study: 24485709

Group type: EXPERIMENTAL
Intervention: Active OIT (peanut flour; protein doses of 2-800 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (peanut avoidance)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Active OIT
Number of subjects: 85
Study: 22077211

Group type: EXPERIMENTAL
Intervention: Bupropion-SR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone
Number of subjects: 0
Study: 19234106

Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercises (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham therapy (n = 15, control)
Number of subjects: 31
Study: 17497371

Group type: EXPERIMENTAL
Intervention: Self-generated strategies
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Endorsed strategies
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Strategic behavior
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Specific strategies for optimal performance
Number of subjects: 85
Study: 15250001

Group type: EXPERIMENTAL
Intervention: Modified hollow stem (Group II)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Solid standard stem (Group I)
Number of subjects: 42
Study: 12881939

Group type: EXPERIMENTAL
Intervention: Experimental group (avoided pacifiers)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control group (used pacifiers)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Daily exposure to pacifiers
Number of subjects: 281
Study: 9828799

Group type: EXPERIMENTAL
Intervention: Broadband ultrasound attenuation (BUA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Speed of sound (SOS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD)
Number of subjects: 75
Study: 7860469

Group type: EXPERIMENTAL
Intervention: Albendazole 15 mg/kg bodyweight/day for 30 days
Number of subjects: 30
Study: 2064878

Group type: EXPERIMENTAL
Intervention: Fentanyl 4.5 micrograms ml‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Adrenaline 4.5 micrograms ml‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Adrenaline plus fentanyl (4.5 micrograms ml‐1 of each)
Number of subjects: 45
Study: 7055401

Group type: EXPERIMENTAL
Intervention: Single dose of tinidazole (1600 mg) and doxycycline (400 mg) before operation
Number of subjects: 234

Group type: COMPARATOR
Intervention: Five days of prophylaxis before operation
Number of subjects: 234
Study: 31044556

Group type: EXPERIMENTAL
Intervention: Ultralow dose CT (100 Sn kV and 96 mA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard dose CT (110 kV and 50 mA)
Number of subjects: 88
Study: 31522147

Group type: EXPERIMENTAL
Intervention: Conventional periodontal treatment (quadrant scaling and root planing - Q-SRP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FM-SRP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (periodontally healthy patients)
Number of subjects: 42
Study: 27732056

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplement, taken twice daily for 8 weeks.
Number of subjects: 0
Study: 24658475

Group type: EXPERIMENTAL
Intervention: Resistance training (10 weeks, 3 x 10 minutes per week)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ergonomic training and education (usual care control group)
Number of subjects: 66
Study: 22839109

Group type: EXPERIMENTAL
Intervention: Diesel combustion particles inhaled during spontaneous breathing
Number of subjects: 10
Study: 19708629

Group type: EXPERIMENTAL
Intervention: Brace and surgery treatment (BS group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Surgery with no brace treatment (S group)
Number of subjects: 94
Study: 17456685

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance combined with nerve stimulation (group US)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nerve stimulation alone (group ES)
Number of subjects: 61
Study: 15045532

Group type: EXPERIMENTAL
Intervention: Autogenous bone (AB)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Bone substitution materials (BSM)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of AB and BSM
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simultaneous SFEA and implantation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Staged approach after an average healing period of 6 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Postoperative sinusitis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall cumulative survival rate of SFEA
Number of subjects: 72
Study: 11976463

Group type: EXPERIMENTAL
Intervention: Daily iron therapy (335 mg of ferrous sulphate and 500 g folic acid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weekly iron therapy (335 mg of ferrous sulphate and 500 g folic acid)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily and weekly iron therapy
Number of subjects: 40
Study: 9951030

Group type: EXPERIMENTAL
Intervention: Riluzol
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study: 8079014

Group type: EXPERIMENTAL
Intervention: Oral clonidine treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 60
Study: 2729160

Group type: EXPERIMENTAL
Intervention: 100% lactose formula
Number of subjects: 6

Group type: COMPARATOR
Intervention: 50% lactose plus 50% glucose polymers formula
Number of subjects: 6
Study: 31545388

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis based on patient-specific risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of anticoagulant therapy perioperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of epinephrine for digital anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clean technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical emollients and petroleum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternatives to elliptical excisions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wound eversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cessation of systemic retinoids
Number of subjects: 0
Study: 28052773

Group type: EXPERIMENTAL
Intervention: Wearable activity monitor (Fitbit® Flex) combined with digital behaviour change resources
Number of subjects: 300

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 300
Study: 26304482

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET)
Number of subjects: 169
Study: 23340042

Group type: EXPERIMENTAL
Intervention: NGT (nasogastric tube feeding)
Number of subjects: 35

Group type: COMPARATOR
Intervention: NPO (nil per os)
Number of subjects: 35
Study: 21314646

Group type: EXPERIMENTAL
Intervention: Brain plasticity‐based computerized cognitive training program
Number of subjects: 487

Group type: COMPARATOR
Intervention: Novelty‐ and intensity‐matched cognitive stimulation active control
Number of subjects: 487
Study: 19624958

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antiplatelets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 20
Study: 16875469

Group type: EXPERIMENTAL
Intervention: Neurobloc (150 and 300 U)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Botox (3 and 4 U)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dysport (12 U)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pure saline
Number of subjects: 10
Study: 13679688

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (medical treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between Immunotherapy and Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Total IgE and specific IgE levels
Number of subjects: 30
Study: 11203593

Group type: EXPERIMENTAL
Intervention: EDTA gel
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Citric acid treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control surgery only
Number of subjects: 68
Study: 9323749

Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 174
Study: 8385183

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril with 12.5 mg HCT
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril with 25 mg HCT
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: 10 mg ramipril with 12.5 mg HCT
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: 10 mg ramipril with 25 mg HCT
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Combination therapy with ramipril plus HCT
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: 25 mg HCT
Number of subjects: 581
Study: 3544182

Group type: EXPERIMENTAL
Intervention: Post-sclerosis variceal compression
Number of subjects: 40

Group type: COMPARATOR
Intervention: No compression
Number of subjects: 40
Study: 30477372

Group type: EXPERIMENTAL
Intervention: Swedish Colorectal Cancer Registry (SCRCR)
Number of subjects: 500
Study: 27871236

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered after spinal anesthesia (Group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dexmedetomidine administered before spinal anesthesia (Group B)
Number of subjects: 74
Study: 24814039

Group type: EXPERIMENTAL
Intervention: Magnesium chloride (30 mL of MgCl2 5% solution) once daily for 3 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: NaHCO3 0.1% solution (control) once daily for 3 months
Number of subjects: 62
Study: 22739364

Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg/day)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study: 20090540

Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscope (FOB)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Blind intubation device (BID)
Number of subjects: 41
Study: 18216056

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone component
Number of subjects: 0
Study: 15970116

Group type: EXPERIMENTAL
Intervention: Home-based educational intervention by nursing staff
Number of subjects: 70
Study: 12582429

Group type: EXPERIMENTAL
Intervention: Immediate imipenem (prophylactic arm)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Delayed imipenem (therapeutic arm)
Number of subjects: 65
Study: 10734844

Group type: EXPERIMENTAL
Intervention: Educational package based on Present State Examination‐9 for initial assessment; duration: not specified
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: File audit tool to evaluate effectiveness of education; duration: not specified
Number of subjects: 20
Study: 8529770

Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Danazol (400 mg/day)
Number of subjects: 19
Study: 1686422

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg QAM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg QHS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6119512

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg 6‐hourly for adults and 40 mg/kg daily for children)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 29
Study: 31226920

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 0
Study: 30153581

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 960

Group type: COMPARATOR
Intervention: Vitamin D replete
Number of subjects: 960
Study: 28347733

Group type: EXPERIMENTAL
Intervention: BCG vaccination (SSI strain 1331)
Number of subjects: 4262

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 4262
Study: 26597740

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day elemental calcium)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 836
Study: 23374761

Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy for 10 weeks delivered by trained occupational therapists.
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no occupational therapy during the study period).
Number of subjects: 192
Study: 21458503

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 10mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ)
Number of subjects: 18
Study: 19575328

Group type: EXPERIMENTAL
Intervention: Participants instructed to generate and apply loci on a route to their work
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants instructed to generate and apply loci on a route in their house
Number of subjects: 0